COVID-19 Vaccine Efficacy and Effectiveness – the Elephant (Not) in the Room

Piero Olliaro, Els Torreele, Michel Vaillant

Vaccine efficacy is generally reported as a relative risk reduction (RRR). It uses the relative risk (RR)—ie, the ratio of attack rates with and without a vaccine—which is expressed as 1–RR…

Although the RRR considers only participants who could benefit from the vaccine, the absolute risk reduction (ARR), which is the difference between attack rates with and without a vaccine, considers the whole population. ARRs tend to be ignored because they give a much less impressive effect size than RRRs: 1·3% for the AstraZeneca–Oxford, 1·2% for the Moderna–NIH, 1·2% for the J&J, 0·93% for the Gamaleya, and 0·84% for the Pfizer–BioNTech vaccines.

… This means in a real-life setting, 1·8 times more subjects might need to be vaccinated to prevent one more case of COVID-19 than predicted in the corresponding clinical trial.

Latest articles

Byram W. Bridle … In response to a great question about a...
Vesanto Melina Soy has been the focus of considerable controversy. The roots...
Mark Messina … Isoflavones are classified as both phytoestrogens and selective estrogen...
BRMI … The lymphatic system lacks an organ that acts as a...
Jiacheng Huang et al. The extracellular matrix (ECM) is one of the...
Joseph Mercola Glyphosate is a very efficient metal chelator. This, in turn,...

Thank you!

Thank you for your membership application. As soon as your payment has been received your membership will be activated and you will be informed via email.

Thank you.

Thank you!

The form has been submitted successfully!